Loading
A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.
CD7 is expressed on ~95% of T-ALL and T-lymphoblastic lymphoma, some NK/T lymphomas and ~30% of AML. CD7 CAR-T requires fratricide prevention (CD7 knockout, protein expression blockers or naturally selected CD7-negative T cells) and causes T-cell aplasia, so it is used as a bridge to allogeneic transplant. Trials in China (Peking University, Hebei Yanda) reported 90%+ complete remission in relapsed T-ALL (NEJM 2022, universal donor-derived CAR-T), and WU-CART-007 (allogeneic, US) received breakthrough status. Also a target for the ADC and for imaging in T-cell lymphoma.
In plain words · A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.
A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.
Ig-superfamily transmembrane glycoprotein on thymocytes, mature T and NK cells; ligand is SECTM1/K12; co-stimulatory role in early T-cell development.
No product in this corpus aims at CD7 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
First described 1987. Earliest sequence paper UniProt cites for the protein: Aruffo et al, EMBO J, 1987, "Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system". Source.
Ig-superfamily transmembrane glycoprotein on thymocytes, mature T and NK cells; ligand is SECTM1/K12; co-stimulatory role in early T-cell development.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute lymphoblastic leukaemia | >99% | Flow cytometry, median % CD7+ blasts in 49 diagnostic T-ALL samples (incl. 14 ETP-ALL); stable at relapse and during chemotherapy | T-ALL/T-LBL only (~15% of ALL); B-ALL is CD7-negative | doi.org |
| Acute myeloid leukaemia | 30% | Flow cytometry, CD7 on leukaemic blasts (approximately 30% of AML patients) | CD7+ AML carries a worse prognosis | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"CD7" OR ABSTRACT:"CD7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD7, not a curated reading list.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.